


We claim:

1. A compound represented by A:



wherein

X represents  $C(R_3)_2$ , O, S, SO,  $SO_2$ ,  $NR_2$ ,  $NC(O)R_1$ ,  $NC(O)OR_2$ ,  $NS(O)_2R_1$ , or  $C=O$ ;

Z represents N or CR;

m is 0, 1, 2, 3 or 4;

n is 1 or 2;

p is 1, 2, or 3;

y is 0, 1, or 2;

R represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

$R_1$  represents  $NR_2$ , alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R and  $R_1$  may be connected through a covalent bond;

$R_2$  represents independently for each occurrence H, alkyl, fluoroalkyl, aryl, heteroaryl, or cycloalkyl;

$R_3$  represents independently for each occurrence H, alkyl, aryl,  $OR_2$ ,  $OC(O)R_2$ ,  $CH_2OR_2$ , or  $CO_2R_2$ ; wherein any two instances of  $R_3$  may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4 carbon atoms;

$R_4$  represents independently for each occurrence H, alkyl, aryl, heteroaryl, alkenyl, or cycloalkyl;

$R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_5R_6$  taken together is  $C(O)$ ;

$R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_8R_9$  taken together is  $C(O)$ ;

Y represents independently for each occurrence  $OR_2$ ,  $N(R_2)_2$ ,  $SR_2$ ,  $S(O)R_2$ ,  $S(O)_2R_2$ , or  $P(O)(OR_2)_2$ ;

any two instances of  $R_2$  may be connected through a covalent bond;

a covalent bond may connect  $R_4$  and an instance of  $R_5$  or  $R_6$ ;


any two instances of  $R_5$  and  $R_6$  may be connected through a covalent bond;

any two geminal or vicinal instances of  $R_8$  and  $R_9$  may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.

2. The compound of claim 1, wherein X is  $C(R_3)_2$ , O, or  $NR_2$ .
3. The compound of claim 1, wherein X is  $C(R_3)_2$ .
4. The compound of claim 1, wherein m is 2.
5. The compound of claim 1, wherein n is 1.
6. The compound of claim 1, wherein y is 1.
7. The compound of claim 1, wherein R represents aryl or heteroaryl.
8. The compound of claim 1, wherein  $R_1$  represents alkyl or aryl.
9. The compound of claim 1, wherein  $R_3$  represents independently for each occurrence H or alkyl.
10. The compound of claim 1, wherein  $R_4$  represents cycloalkyl, aryl, or heteroaryl.
11. The compound of claim 1, wherein  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
12. The compound of claim 1, wherein  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
13. The compound of claim 1, wherein X is  $C(R_3)_2$ ; and m is 2.

14. The compound of claim 1, wherein X is  $C(R_3)_2$ ; and n is 1.
15. The compound of claim 1, wherein X is  $C(R_3)_2$ ; and y is 1.
16. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; and y is 1.
17. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; and R is aryl or heteroaryl.
18. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; R is aryl or heteroaryl; and  $R_1$  represents alkyl or aryl.
19. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; R is aryl or heteroaryl;  $R_1$  represents alkyl or aryl; and  $R_3$  represents independently for each occurrence H or alkyl.
20. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; R is aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl; and  $R_4$  represents cycloalkyl, aryl, or heteroaryl.
21. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; R is aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl;  $R_4$  represents cycloalkyl, aryl, or heteroaryl; and  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
22. The compound of claim 1, wherein X is  $C(R_3)_2$ ; m is 2; n is 1; y is 1; R is aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl;  $R_4$  represents cycloalkyl, aryl, or heteroaryl;  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F; and  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
23. A compound represented by **B**:



B

wherein

Z represents N or CR;

m is 0, 1, 2, 3 or 4;

p is 1, 2, or 3;

y is 0, 1 or 2;

R represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R<sub>1</sub> represents NR<sub>2</sub>, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R and R<sub>1</sub> may be connected through a covalent bond;

R<sub>2</sub> represents independently for each occurrence H, alkyl, fluoroalkyl, aryl, heteroaryl, or cycloalkyl;

R<sub>3</sub> represents independently for each occurrence H, alkyl, aryl, OR<sub>2</sub>, OC(O)R<sub>2</sub>, CH<sub>2</sub>OR<sub>2</sub>, or CO<sub>2</sub>R<sub>2</sub>;

R<sub>4</sub> represents H, alkyl, aryl, heteroaryl, alkenyl, or cycloalkyl;

R<sub>5</sub> and R<sub>6</sub> are selected independently for each occurrence from the group consisting of H, alkyl, (CH<sub>2</sub>)<sub>p</sub>Y, aryl, heteroaryl, F, OR<sub>2</sub>, and OC(O)R<sub>2</sub>; or an instance of CR<sub>5</sub>R<sub>6</sub> taken together is C(O);

R<sub>8</sub> and R<sub>9</sub> are selected independently for each occurrence from the group consisting of H, alkyl, (CH<sub>2</sub>)<sub>p</sub>Y, aryl, heteroaryl, F, OR<sub>2</sub>, and OC(O)R<sub>2</sub>; or an instance of CR<sub>8</sub>R<sub>9</sub> taken together is C(O);

Y represents independently for each occurrence  $OR_2$ ,  $N(R_2)_2$ ,  $SR_2$ ,  $S(O)R_2$ ,  $S(O)_2R_2$ , or  $P(O)(OR_2)_2$ ;

any two instances of  $R_2$  may be connected through a covalent bond;

a covalent bond may connect  $R_4$  and an instance of  $R_5$  or  $R_6$ ;

any two instances of  $R_5$  and  $R_6$  may be connected through a covalent bond;

any two geminal or vicinal instances of  $R_8$  and  $R_9$  may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by **B** is *R*, *S*, or a mixture of these configurations.

24. The compound of claim 23, wherein *m* is 2.

25. The compound of claim 23, wherein *y* is 1.

26. The compound of claim 23, wherein *R* represents aryl or heteroaryl.

27. The compound of claim 23, wherein  $R_1$  represents alkyl or aryl.

28. The compound of claim 23, wherein  $R_3$  represents independently for each occurrence H or alkyl.

29. The compound of claim 23, wherein  $R_4$  represents cycloalkyl, aryl, or heteroaryl.

30. The compound of claim 23, wherein  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.

31. The compound of claim 23, wherein  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.

32. The compound of claim 23, wherein *m* is 2; and *y* is 1.

33. The compound of claim 23, wherein *m* is 2; *y* is 1; and *R* represents aryl or heteroaryl.

34. The compound of claim 23, wherein *m* is 2; *y* is 1; *R* represents aryl or heteroaryl; and  $R_1$  represents alkyl or aryl.


35. The compound of claim 23, wherein *m* is 2; *y* is 1; *R* represents aryl or heteroaryl;  $R_1$  represents alkyl or aryl; and  $R_3$  represents independently for each occurrence H or alkyl.

36. The compound of claim 23, wherein m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; and R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl.

37. The compound of claim 23, wherein m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl; and R<sub>5</sub> and R<sub>6</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F.

38. The compound of claim 23, wherein m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl; R<sub>5</sub> and R<sub>6</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F; and R<sub>8</sub> and R<sub>9</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F.

39. A compound represented by C:



wherein

Z represents N or CR;

m is 0, 1, 2, 3 or 4;

p is 1, 2, or 3;

y is 0, 1 or 2;

R represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

$R_1$  represents  $NR_2$ , alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

$R$  and  $R_1$  may be connected through a covalent bond;

$R_2$  represents independently for each occurrence H, alkyl, fluoroalkyl, aryl, heteroaryl, or cycloalkyl;

$R_3$  represents independently for each occurrence H, alkyl, aryl,  $OR_2$ ,  $OC(O)R_2$ ,  $CH_2OR_2$ , or  $CO_2R_2$ ;

$R_4$  represents H, alkyl, aryl, heteroaryl, alkenyl, or cycloalkyl;

$R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_5R_6$  taken together is  $C(O)$ ;

$R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_8R_9$  taken together is  $C(O)$ ;

$Y$  represents independently for each occurrence  $OR_2$ ,  $N(R_2)_2$ ,  $SR_2$ ,  $S(O)R_2$ ,  $S(O)_2R_2$ , or  $P(O)(OR_2)_2$ ;

any two instances of  $R_2$  may be connected through a covalent bond;

a covalent bond may connect  $R_4$  and an instance of  $R_5$  or  $R_6$ ;

any two instances of  $R_5$  and  $R_6$  may be connected through a covalent bond;

any two geminal or vicinal instances of  $R_8$  and  $R_9$  may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by  $C$  is  $R$  or  $S$ , or a mixture of these configurations.

40. The compound of claim 39, wherein  $m$  is 2.

41. The compound of claim 39, wherein  $y$  is 1.

42. The compound of claim 39, wherein  $R$  represents aryl or heteroaryl.


43. The compound of claim 39, wherein  $R_1$  represents alkyl or aryl.

44. The compound of claim 39, wherein  $R_3$  represents independently for each occurrence H or alkyl.

45. The compound of claim 39, wherein  $R_4$  represents cycloalkyl, aryl, or heteroaryl.

46. The compound of claim 39, wherein  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
47. The compound of claim 39, wherein  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
48. The compound of claim 39, wherein  $m$  is 2; and  $y$  is 1.
49. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1; and  $R$  represents aryl or heteroaryl.
50. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1;  $R$  represents aryl or heteroaryl; and  $R_1$  represents alkyl or aryl.
51. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1;  $R$  represents aryl or heteroaryl;  $R_1$  represents alkyl or aryl; and  $R_3$  represents independently for each occurrence H or alkyl.
52. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1;  $R$  represents aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl; and  $R_4$  represents cycloalkyl, aryl, or heteroaryl.
53. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1;  $R$  represents aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl;  $R_4$  represents cycloalkyl, aryl, or heteroaryl; and  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
54. The compound of claim 39, wherein  $m$  is 2;  $y$  is 1;  $R$  represents aryl or heteroaryl;  $R_1$  represents alkyl or aryl;  $R_3$  represents independently for each occurrence H or alkyl;  $R_4$  represents cycloalkyl, aryl, or heteroaryl;  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F; and  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.
55. A compound represented by D:





D

wherein

X represents  $C(R_3)_2$ , O, S, SO,  $SO_2$ ,  $NR_2$ ,  $NC(O)R_1$ ,  $NC(O)OR_2$ ,  $NS(O)_2R_1$ , or  $C=O$ ;

Z represents N or CR;

m is 0, 1, 2, 3 or 4;

p is 1, 2, or 3;

y is 0, 1, or 2;

R represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

$R_1$  represents  $NR_2$ , alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R and  $R_1$  may be connected through a covalent bond;

$R_2$  represents independently for each occurrence H, alkyl, fluoroalkyl, aryl, heteroaryl, or cycloalkyl;

$R_3$  represents independently for each occurrence H, alkyl, aryl,  $OR_2$ ,  $OC(O)R_2$ ,  $CH_2OR_2$ , or  $CO_2R_2$ ;

$R_4$  represents independently for each occurrence H, alkyl, aryl, heteroaryl, alkenyl, or cycloalkyl;

$R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_5R_6$  taken together is  $C(O)$ ;

$R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $(CH_2)_pY$ , aryl, heteroaryl, F,  $OR_2$ , and  $OC(O)R_2$ ; or an instance of  $CR_8R_9$  taken together is  $C(O)$ ;

Y represents independently for each occurrence  $OR_2$ ,  $N(R_2)_2$ ,  $SR_2$ ,  $S(O)R_2$ ,  $S(O)_2R_2$ , or  $P(O)(OR_2)_2$ ;

any two instances of  $R_2$  may be connected through a covalent bond;

a covalent bond may connect  $R_4$  and an instance of  $R_5$  or  $R_6$ ;

any two instances of  $R_5$  and  $R_6$  may be connected through a covalent bond;

any two geminal or vicinal instances of  $R_8$  and  $R_9$  may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by **D** is *R*, *S*, or a mixture of these configurations.

56. The compound of claim 55, wherein X is O or  $NR_2$ .

57. The compound of claim 55, wherein m is 2.

58. The compound of claim 55, wherein y is 1.

59. The compound of claim 55, wherein R represents aryl or heteroaryl.

60. The compound of claim 55, wherein  $R_1$  represents alkyl or aryl.

61. The compound of claim 55, wherein  $R_3$  represents independently for each occurrence H or alkyl.

62. The compound of claim 55, wherein  $R_4$  represents cycloalkyl, aryl, or heteroaryl.

63. The compound of claim 55, wherein  $R_5$  and  $R_6$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.

64. The compound of claim 55, wherein  $R_8$  and  $R_9$  are selected independently for each occurrence from the group consisting of H, alkyl,  $OR_2$ , aryl, heteroaryl, and F.

65. The compound of claim 55, wherein X is O or  $NR_2$ ; and m is 2.

66. The compound of claim 55, wherein X is O or  $NR_2$ ; and y is 1.

67. The compound of claim 55, wherein X is O or  $NR_2$ ; m is 2; and y is 1.

68. The compound of claim 55, wherein X is O or  $NR_2$ ; m is 2; y is 1; and R represents aryl or heteroaryl.

69. The compound of claim 55, wherein X is O or NR<sub>2</sub>; m is 2; y is 1; R represents aryl or heteroaryl; and R<sub>1</sub> represents alkyl or aryl.

70. The compound of claim 55, wherein X is O or NR<sub>2</sub>; m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; and R<sub>3</sub> represents independently for each occurrence H or alkyl.

71. The compound of claim 55, wherein X is O or NR<sub>2</sub>; m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; and R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl.

72. The compound of claim 55, wherein X is O or NR<sub>2</sub>; m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl; and R<sub>5</sub> and R<sub>6</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F.

73. The compound of claim 55, wherein X is O or NR<sub>2</sub>; m is 2; y is 1; R represents aryl or heteroaryl; R<sub>1</sub> represents alkyl or aryl; R<sub>3</sub> represents independently for each occurrence H or alkyl; R<sub>4</sub> represents cycloalkyl, aryl, or heteroaryl; R<sub>5</sub> and R<sub>6</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F; and R<sub>8</sub> and R<sub>9</sub> are selected independently for each occurrence from the group consisting of H, alkyl, OR<sub>2</sub>, aryl, heteroaryl, and F.

74. The compound of claim 1, 23, 39, or 55, wherein said compound is a single stereoisomer.

75. The compound of claim 1, 23, 39, or 55, wherein said compound has an IC<sub>50</sub> less than 1 μM in an assay based on a mammalian GPCR or ligand-gated ion channel.

76. The compound of claim 1, 23, 39, or 55, wherein said compound has an IC<sub>50</sub> less than 100 nM in an assay based on a mammalian GPCR or ligand-gated ion channel.

77. The compound of claim 1, 23, 39, or 55, wherein said compound has an IC<sub>50</sub> less than 10 nM in an assay based on a mammalian GPCR or ligand-gated ion channel.

78. The compound of claim 1, 23, 39, or 55, wherein said compound has an IC<sub>50</sub> less than 1 μM in an assay based on a mammalian GPCR.

79. The compound of claim 41, wherein said mammalian GPCR is an NMDA receptor, a norepinephrine transporter or a sigma receptor.
80. The compound of claim 1, 12, 20, or 28, wherein said compound has an  $IC_{50}$  less than 100 nM in an assay based on a mammalian GPCR.
81. The compound of claim 80, wherein said mammalian GPCR is an NMDA receptor, a norepinephrine transporter or a sigma receptor.
82. The compound of claim 1, 23, 39, or 55, wherein said compound has an  $IC_{50}$  less than 10 nM in an assay based on a mammalian GPCR.
83. The compound of claim 82, wherein said mammalian GPCR is an NMDA receptor, a norepinephrine transporter or a sigma receptor.
84. A formulation, comprising a compound of claim 1, 23, 39, or 55; and a pharmaceutically acceptable excipient.
85. A method of treating an acute or chronic ailment, disease or malady in a mammal that is due to an abnormality in a biochemical or physiological process associated with a G-protein-coupled receptor or ligand-gated ion channel, comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 1, 23, 39, or 55.
86. The method of claim 85, wherein said mammal is a primate, equine, canine or feline.
87. The method of claim 85, wherein said mammal is a human.
88. The method of claim 85, wherein said compound is administered orally.
89. The method of claim 85, wherein said compound is administered intravenously.
90. The method of claim 85, wherein said compound is administered sublingually.
91. The method of claim 85, wherein said compound is administered ocularly.
92. The method of claim 85, wherein said compound is administered transdermally.
93. The method of claim 85, wherein said compound is administered rectally.
94. The method of claim 85, wherein said compound is administered vaginally.
95. The method of claim 85, wherein said compound is administered nasally.

96. A method of treating a psychiatric disorder in a mammal, comprising the step of:  
administering to said mammal a therapeutically effective amount of a compound  
of claim 1, 23, 39, or 55.
97. The method of claim 96, wherein said psychiatric disorder is a psychosis.
98. The method of claim 96, wherein said psychiatric disorder is schizophrenia.
99. The method of claim 96, wherein said psychiatric disorder is paranoia, manic depression,  
or depression.
100. The method of claim 96, wherein said mammal is a primate, equine, canine or feline.
101. The method of claim 96, wherein said mammal is a human.
102. The method of claim 96, wherein said compound is administered orally.
103. The method of claim 96, wherein said compound is administered intravenously.
104. The method of claim 96, wherein said compound is administered sublingually.
105. The method of claim 96, wherein said compound is administered ocularly.
106. The method of claim 96, wherein said compound is administered transdermally.
107. The method of claim 96, wherein said compound is administered rectally.
108. The method of claim 96, wherein said compound is administered vaginally.
109. The method of claim 96, wherein said compound is administered nasally.
110. A method of treating a mammal suffering from an anxiety disorder, a dissociative  
disorder, a mood disorder, a personality disorder, a psychosexual disorder, an eating disorder,  
drug addiction, drug dependence, depression, manic depression, paranoia, psychosis,  
schizophrenia, or inflammatory pain, comprising the step of:  
administering to said mammal a therapeutically effective amount of a compound  
of claim 1, 23, 39, or 55.
111. The method of claim 110, wherein said mammal is a primate, equine, canine or feline.
112. The method of claim 110, wherein said mammal is a human.
113. The method of claim 110, wherein said compound is administered orally.

114. The method of claim 110, wherein said compound is administered intravenously.
115. The method of claim 110, wherein said compound is administered sublingually.
116. The method of claim 110, wherein said compound is administered ocularly.
117. The method of claim 110, wherein said compound is administered transdermally.
118. The method of claim 110, wherein said compound is administered rectally.
119. The method of claim 110, wherein said compound is administered vaginally.
120. The method of claim 110, wherein said compound is administered nasally.